Rafferty Asset Management
DNLI icon

Rafferty Asset Management’s Denali Therapeutics DNLI Stock Holding History

Rafferty Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.48M Sell
96,342
-54,345
-36% -$1.12M 0.01% 592
2026
Q1 		$2.89M Sell
150,687
-40,880
-21% -$813K 0.01% 521
2025
Q4 		$3.16M Buy
191,567
+8,681
+5% +$147K 0.01% 543
2025
Q3 		$2.66M Buy
182,886
+60,624
+50% +$871K 0.01% 576
2025
Q2 		$1.71M Sell
122,262
-6,873
-5% -$96.7K 0.01% 638
2025
Q1 		$1.76M Sell
129,135
-12,175
-9% -$233K 0.01% 609
2024
Q4 		$2.88M Buy
141,310
+23,629
+20% +$605K 0.01% 541
2024
Q3 		$3.43M Sell
117,681
-33,801
-22% -$838K 0.01% 496
2024
Q2 		$3.52M Sell
151,482
-283,427
-65% -$5.44M 0.01% 492
2024
Q1 		$8.92M Buy
434,909
+112,936
+35% +$2.12M 0.03% 306
2023
Q4 		$6.91M Buy
321,973
+92,660
+40% +$1.84M 0.03% 374
2023
Q3 		$4.73M Sell
229,313
-19,213
-8% -$487K 0.03% 396
2023
Q2 		$7.33M Sell
248,526
-8,447
-3% -$238K 0.04% 323
2023
Q1 		$5.92M Sell
256,973
-26,769
-9% -$737K 0.04% 346
2022
Q4 		$7.89M Buy
283,742
+76,374
+37% +$2.27M 0.07% 267
2022
Q3 		$6.36M Buy
207,368
+105,897
+104% +$3.44M 0.07% 266
2022
Q2 		$2.99M Sell
101,471
-74,491
-42% -$1.95M 0.03% 392
2022
Q1 		$5.66M Buy
175,962
+54,207
+45% +$1.87M 0.03% 354
2021
Q4 		$5.43M Buy
121,755
+61,394
+102% +$2.91M 0.03% 359
2021
Q3 		$3.04M Buy
60,361
+25,581
+74% +$1.44M 0.02% 471
2021
Q2 		$2.73M Sell
34,780
-16,725
-32% -$1.03M 0.02% 538
2021
Q1 		$2.94M Buy
51,505
+39,855
+342% +$2.67M 0.02% 508
2020
Q4 		$976K Sell
11,650
-27,468
-70% -$1.66M 0.01% 501
2020
Q3 		$1.4M Buy
39,118
+22,118
+130% +$666K 0.02% 516
2020
Q2 		$411K Buy
+17,000
New +$400K 0.01% 756
2020
Q1 		– Sell
-28,690
Closed -$500K – 655
2019
Q4 		$500K Sell
28,690
-27,690
-49% -$461K 0.01% 689
2019
Q3 		$864K Sell
56,380
-22,541
-29% -$431K 0.01% 570
2019
Q2 		$1.64M Buy
78,921
+28,178
+56% +$631K 0.03% 464
2019
Q1 		$1.18M Buy
+50,743
New +$1.06M 0.02% 519

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rafferty Asset Management's DNLI Position: Q2 2026 in Review

Rafferty Asset Management reduced its Denali Therapeutics (DNLI) stake by 36% in Q2 2026, selling an estimated $1.12M and leaving 96,342 shares worth $2.48M. The position accounts for 0.01% of the portfolio, ranked #592.

Rafferty Asset Management first reported a position in DNLI in Q1 2019 and has held it in 29 quarters since. The position peaked at $8.92M in Q1 2024. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Rafferty Asset Management held 96,342 shares of Denali Therapeutics worth $2.48M as of Q2 2026.
  • Rafferty Asset Management sold 54,345 Denali Therapeutics shares in Q2 2026, an estimated $1.12M.
  • Denali Therapeutics made up 0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #592 holding.
  • Rafferty Asset Management first reported a position in Denali Therapeutics in Q1 2019 and has held it in 29 quarters since.
  • Rafferty Asset Management's Denali Therapeutics position peaked at $8.92M in Q1 2024.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.